Tyler Adam, MD, Coauthors NEJM Article With Results From Phase 3 Maternal RSV Vaccine Study

Tyler Adam, MD, Principal Investigator at Velocity Clinical Research in Hastings, NE, supported the promising MATISSE Phase 3 maternal RSV vaccine study — results of which have been published in the article, “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants” in the New England Journal of Medicine. In this global trial, for which Dr. Adam and his team were a leading enroller, the investigational vaccine demonstrated efficacy of 81.8% against severe RSV cases in infants within 90 days of birth and 69.4% within 180 days of birth. Read more: https://www.nejm.org/doi/full/10.1056/NEJMoa2216480

Posted in

Quality. Continuity. Velocity.